The KDM3B antibody targets the KDM3B protein, a member of the lysine (K)-specific demethylase 3 family, which plays a critical role in epigenetic regulation. KDM3B, also known as JMJD1B or JHDM2B, is a histone demethylase that specifically removes methyl groups from histone H3 lysine 9 (H3K9me2/me1), a post-translational modification associated with transcriptional repression. By demethylating H3K9. KDM3B facilitates gene activation and chromatin remodeling, influencing processes such as cell proliferation, differentiation, metabolic homeostasis, and DNA damage repair. Dysregulation of KDM3B has been implicated in various cancers, including prostate, breast, and liver cancers, where its overexpression often correlates with tumor progression, metastasis, and therapy resistance. Additionally, KDM3B is involved in metabolic disorders and neurodegenerative diseases, highlighting its broad biological significance. Antibodies against KDM3B are essential tools for studying its expression, localization, and function in both normal and pathological contexts. They are widely used in techniques like Western blotting, immunoprecipitation, and immunofluorescence to explore its role in epigenetic mechanisms and potential as a therapeutic target. Researchers also utilize these antibodies to assess the efficacy of KDM3B inhibitors in preclinical models.